tiprankstipranks
Trending News
More News >

hVIVO plc Announces Option Exercise and Share Issuance

Story Highlights

Protect Your Portfolio Against Market Uncertainty

Open Orphan Plc ( (GB:HVO) ) has shared an announcement.

hVIVO plc announced the exercise of 202,092 options by employees, including the Chief Financial Officer, Stephen Pinkerton, under the company’s 2020 Long Term Incentive Plan. This transaction will result in the issuance of new ordinary shares, increasing the total number of shares in issue to 687,014,088, with equal voting rights. This development reflects the company’s ongoing commitment to incentivizing its employees and could impact its market positioning by potentially increasing shareholder value.

More about Open Orphan Plc

hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. It specializes in human challenge trials for infectious and respiratory diseases, utilizing its state-of-the-art quarantine facility in London. hVIVO also offers virology and immunology laboratory services under the hLAB brand and operates clinical trial services in Germany through its subsidiary CRS. Another subsidiary, Venn Life Sciences, provides consulting and biometry services to the biopharma sector.

YTD Price Performance: -27.80%

Average Trading Volume: 3,219,357

Technical Sentiment Signal: Strong Buy

Current Market Cap: £98.21M

See more data about HVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App